🇺🇸 FDA
Pipeline program

POMALIDOMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, BORTEZOMIB, POMALIDOMIDE, CARFILZOMIB, POMALIDOMIDE, CARFILZOMIB, DEXAMETHASONE

224317

Phase 2 small_molecule active

Quick answer

POMALIDOMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, BORTEZOMIB, POMALIDOMIDE, CARFILZOMIB, POMALIDOMIDE, CARFILZOMIB, DEXAMETHASONE for Relapsed or Refractory Multiple Myeloma is a Phase 2 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline Biologicals S.A.
Indication
Relapsed or Refractory Multiple Myeloma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials